The Assessing Patients' Preferred Treatments (APPT-1) study

International Journal of STD and AIDS

Volumn 14, Issue SUPPL. 1, 2003, Pages 34-36

  Moyle, G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Adherence; HIV infection; Once daily

Indexed keywords

ABACAVIR; AMDOXOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RITONAVIR; TENOFOVIR; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; INTERVIEWS; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION;

EID: 0242298694     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646203322491860     Document Type: Conference Paper

References (12)

1. Sanne I, Cahn P, Percival L, et al. Comparative results (Phase II 48-Week): BMS-232632, stavudine, lamivudine as HAART for treatment-naïve HIV(+) patients (AI424-008) [Poster I-667], 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago 2001
2. Van Leth F, Hassinck E, Phanuphak P, et al. Results of the 2NN Study: A randomized comparative trial of 1st line antiretroviral therapy (ART) with regimens containing either nevirapine (NVP) alone, efavirenz (EFV) alone or both drugs combined together with stavudine and lamivudine. (2NN Study) [Abstract No. 176]. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003
3. Squires KE, Thiry A, Giordano M, et al. Atazanavir (ATV) QD vs efavirenz (EFV) QD with fixed-dose ZDV+3TC BID: Comparison of antiviral efficacy and safety 48-week results from BMS AI424-034 Phase III Pivotal Study [Abstract H-1076]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 2002
4. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
5. Bass D, Smith MF. HIV patients prefer once-daily regimens [Abstract MOPeB3290]. XIV International AIDS Conference, Barcelona 2002
6. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immunol Defic Syndr 2000;23:386-95
7. Walsh JC, Horne R, Dalton M, et al. Reasons for non-adherence to antiretroviral therapy: patients' perspectives provide evidence of multiple causes. AIDS Care 2001;13:709-20
8. Park-Wyllie LY, Scalera A, Tseng A, et al. High rate of discontinuations of highly active antiretroviral therapy as a result of antiretroviral intolerance in clinical practice: missed opportunities for adherence support? AIDS 2002;16:1084-6
9. The AWARE Talk Radio Poll; 2001-2002; The AIDS Talk Radio Project in conjunction with The Core Center; AIDS Research Alliance; Howard Brown Health Center; an Internet survey. Chicago: Howard Brown Health Center, 2002
10. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral naïve HIV-1 infected adults. AIDS 15:1369-77
11. Maggiolo F, Arici C, Gregis GP, et al. A controlled, randomised, prospective study on a once-a-day therapy for HIV infection [Abstract H-163]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 2002
12. Fischl MA, Castro J, Monroig R, et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials [Abstract 528]. 8th Conference on Retroviruses and Opportunistic Infections, Chicago 2001